Treatment of Alcohol Withdrawal Seizures

First-Line Pharmacological Treatment

Long-acting benzodiazepines, such as diazepam and chlordiazepoxide, are recommended for prevention of alcohol withdrawal seizures through GABA activation, as suggested by the American Association for the Study of Liver Diseases 1, 3
Standard dosing for diazepam is 5-10 mg every 6-8 hours via oral, intravenous, or intramuscular routes, with a strength of evidence level of high 3, 4
Chlordiazepoxide can be administered at 25-100 mg every 4-6 hours orally, with a moderate level of evidence 3, 5

Lorazepam (intermediate-acting benzodiazepine) is preferred for patients with severe alcohol withdrawal syndrome, advanced age, recent head trauma, liver failure or hepatic dysfunction, respiratory failure, or obesity, due to its safer pharmacokinetic profile, as recommended by the American College of Clinical Pharmacology 3, 4, 5, 6, 7
Lorazepam dosing typically starts at 6-12 mg/day (1-4 mg every 4-8 hours) and is tapered following resolution of withdrawal symptoms, with a strength of evidence level of moderate 5, 10

Carbamazepine (200 mg every 6-8 hours) is an effective alternative to benzodiazepines for seizure prevention in alcohol withdrawal, with a moderate level of evidence, as suggested by the National Institute on Alcohol Abuse and Alcoholism 3, 5
Thiamine (100-300 mg/day) must be administered to all patients with alcohol withdrawal to prevent Wernicke encephalopathy, with a high level of evidence, as recommended by the American Medical Association 3, 10

Inpatient treatment is strongly recommended for cases with seizures due to alcohol withdrawal, with a high level of evidence, as suggested by the Society of Hospital Medicine 3, 4
The CIWA-Ar score can guide treatment intensity—scores >8 indicate moderate AWS and scores ≥15 indicate severe AWS requiring more aggressive treatment, with a moderate level of evidence, as recommended by the American Society of Addiction Medicine 1, 10

Benzodiazepine treatment should not exceed 10-14 days to avoid the risk of dependence, with a high level of evidence, as suggested by the World Health Organization 2, 11
The CIWA protocol is not recommended for diagnosis of AWS as high scores may be seen in other conditions, with a moderate level of evidence, as recommended by the European Association for the Study of the Liver 3, 5